

Disclosures

Personal Commercial (32)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Vascular	Other - <i>Research grant/SAB</i>	None (\$0)	Valvular Heart Disease
Adona	Other - <i>SAB equity/Consultant</i>	None (\$0)	Heart Failure and Cardiomyopathies
Akura	Other - <i>Equity</i>	None (\$0)	Valvular Heart Disease
Anteris	Other - <i>Equity/SAB</i>	None (\$0)	Valvular Heart Disease
Bonaparte	Other - <i>Equity</i>	None (\$0)	Valvular Heart Disease
Boston Scientific	Other - <i>Research grant/SAB</i>	None (\$0)	Valvular Heart Disease
Cardiomech	Other - <i>Stock/Consultant</i>	Significant (>= \$5,000)	Valvular Heart Disease
Dura Biotech	Other - <i>Equity/SAB</i>	Modest (< \$5,000)	Valvular Heart Disease
Edwards Lifesciences	Research/Research Grants <i>‡ Triscend, PASCAL TR</i>	None (\$0)	Valvular Heart Disease
Emboliner	Research/Research Grants	None (\$0)	Valvular Heart Disease
Helix Valve Repair	Other - <i>Consultant/Equity</i>	Significant (>= \$5,000)	Valvular Heart Disease
JenaValve	Research/Research Grants	None (\$0)	Valvular Heart Disease
Meacor	Other - <i>Consultant/Equity</i>	Modest (< \$5,000)	Valvular Heart Disease
Medtronic	Other - <i>Research grant/SAB</i>	None (\$0)	Valvular Heart Disease
MicroInterventional Devices	Other - <i>Equity - SAB/Consultant</i>	None (\$0)	Valvular Heart Disease
Moray Medical	Consultant Fees/Honoraria	None (\$0)	Valvular Heart Disease
Nyra	Other - <i>Consultant/Equity</i>	Significant (>= \$5,000)	Valvular Heart Disease
Phillips	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions
Protembis	Research/Research Grants	None (\$0)	Valvular Heart Disease
Relief Cardiovascular	Other - <i>Equity</i>	None (\$0)	Valvular Heart Disease
Reniva	Other - <i>Consultant/Equity</i>	Modest (< \$5,000)	Valvular Heart Disease
Shifamed	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions
Supira	Other - <i>Equity SAB equity/Consultant/Honoraria</i>	Modest (< \$5,000)	Invasive CV Angio and Interventions
Thubrikar Aortic Valve, Inc	Other - <i>SAB Equity</i>	None (\$0)	Valvular Heart Disease
Tioga	Other - <i>SAB equity/Consultant/Honoraria</i>	Significant (>= \$5,000)	Valvular Heart Disease
Trajectory	Other - <i>Consultant/Equity</i>	Modest (< \$5,000)	Valvular Heart Disease
Tricare	Research/Research Grants <i>‡ Tricare</i>	None (\$0)	Valvular Heart Disease
TriFlo	Other - <i>Equity - SAB/Consultant</i>	None (\$0)	Valvular Heart Disease
Trisol	Research/Research Grants	None (\$0)	Valvular Heart Disease
V2V	Other - <i>Equity</i>	None (\$0)	Valvular Heart Disease
Vdyne	Research/Research Grants	None (\$0)	Valvular Heart Disease
X-Dot	Other - <i>Stock/Consultant/Honoraria</i>	Significant (>= \$5,000)	Valvular Heart Disease

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/31/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/31/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

Embargo | Signed on 10/31/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

On-Going Obligation Agreement | Signed on 10/31/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.